What's happening
On June 22, 2026, Regenxbio disclosed that it has reached alignment with the U.S. Food and Drug Administration on a regulatory path forward for the resubmission of its Biologics License Application for NAVSUNLI (RGX-121), its investigational gene therapy for mucopolysaccharidosis type II, commonly known as Hunter syndrome. The announcement represents a reversal of the FDA's prior stance: the agency had issued a Complete Response Letter on or around February 7–9, 2026, effectively rejecting the application at that time and triggering a stock decline of between 14% and 19%, with shares falling to $8.31 in aftermarket trading following that decision.
The resubmission will seek accelerated approval, the same regulatory mechanism under which the original BLA was accepted in May 2025. NAVSUNLI, also designated RGX-121, is built on Regenxbio's proprietary NAV Technology Platform, which uses adeno-associated virus vectors to deliver genetic material. If ultimately approved, NAVSUNLI would represent the first gene therapy cleared by the FDA specifically for Hunter syndrome, a rare, progressive, and life-threatening lysosomal storage disorder that primarily affects male children.
Why it matters for markets
The regulatory reversal carries direct financial implications for Regenxbio, a company with a current market capitalization of approximately $403.2 million and annual revenue of $87.8 million. The February 2026 Complete Response Letter had already demonstrated the market's sensitivity to this program, with shares declining 14–19% on that news. The BLA resubmission pathway now reopens the possibility of accelerated approval — a mechanism designed for serious conditions where a therapy demonstrates an effect on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit — which could shorten the timeline to a potential commercial launch relative to a standard approval process.
For the rare disease biotechnology sector more broadly, the first-in-class designation of NAVSUNLI is a material consideration. Hunter syndrome affects a small patient population, and no gene therapy has previously been approved for the indication, meaning a successful approval would establish Regenxbio in a market with no direct gene-therapy competition at launch. The company's NAV Technology Platform also underpins its broader pipeline, including RGX-314 for wet age-related macular degeneration and diabetic retinopathy, as well as its licensing revenue stream — meaning the credibility of the platform itself is partially tied to the regulatory outcome of RGX-121.
The accelerated approval pathway, while potentially expediting market entry, also carries conditions: the FDA typically requires confirmatory trials to verify clinical benefit post-approval, and therapies approved under this mechanism remain subject to withdrawal if confirmatory evidence does not materialize. The specific deficiencies cited in the February 2026 CRL, and the nature of the FDA's alignment on the resubmission path, will be critical factors in assessing the durability of any approval that may follow.
Sectors and assets to watch
The primary ticker directly affected by this development is RGNX (Regenxbio Inc.), which is the sponsor of the NAVSUNLI BLA and the entity that announced the FDA alignment. With a 52-week range of $5.46 to $16.19 and a current price of $7.80, the stock remains well below the upper end of its annual range, which was established prior to the February 2026 CRL. The BLA resubmission timeline and any subsequent FDA action date will be the key near-term catalysts for this name.
More broadly, the development is relevant to the rare disease gene therapy subsector, where accelerated approval pathways have become a central regulatory strategy for companies targeting small patient populations with high unmet medical need. Other gene therapy developers working within the AAV vector space and pursuing rare pediatric indications may view the FDA's willingness to re-engage with Regenxbio as a data point regarding the agency's current posture toward this class of therapies, though the specific circumstances of each program differ.
What to watch next
Key developments to monitor include the formal resubmission of the NAVSUNLI BLA and any FDA-assigned Prescription Drug User Fee Act action date, which would establish a target decision timeline; the specific manufacturing, clinical, or chemistry-related deficiencies that were identified in the February 2026 CRL and whether Regenxbio's resubmission package is deemed to have adequately addressed them; and any FDA advisory committee meeting that may be convened as part of the review process. Additionally, the terms of any accelerated approval — including the scope and timeline of required confirmatory trials — will shape the commercial and financial trajectory of the program if approval is granted.